# US 2021/0079342 A1 · Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079342 A1
- Document ID: US20210079342A1
- Status: Published application
- Kind: A1
- Application number: 17/097,023
- Filed: 2020-11-13
- Published: 2021-03-18
- Earliest claimed: 2009-11-12
- Assignees: Technion Research & Development Foundation Limited
- Applicants: Technion Research & Development Foundation Limited
- Inventors: Michal AMIT; Joseph ITSKOVITZ-ELDOR
- Web page: https://patentgrep.com/patent/US20210079342A1

## CPC

- C12N 5/0602: {Vertebrate cells}
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 2500/36: Lipids
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2500/92: Medium free of human- or animal-derived components
- C12N 2500/98: Xeno-free medium and culture conditions
- C12N 2500/99: Serum-free medium
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/23: Interleukins [IL]
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are novel serum-free culture media which comprise basic fibroblast growth factor (bFGF), transforming growth factor beta-3 and ascorbic acid at a concentration of at least about 50 microgram/ml; ascorbic acid at a concentration range of about 400-600 microgram/ml, bFGF at a concentration range of about 50-200 ng/ml, xeno-free serum replacement and a lipid mixture; the IL6RIL6 chimera at a concentration range of about 50-200 picogram per milliliter (pg/ml); or leukemia inhibitory factor (LIF) at a concentration of at least 2000 units/ml; cell cultures comprising same with pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem (iPS) cells, and methods of using same for expanding pluripotent stem cells in an undifferentiated state using two-dimensional or three-dimensional culture systems; and methods of expanding iPS cells in a suspension culture devoid of substrate adherence and cell encapsulation.

## Claims

### Claim 1

A culture medium comprising an IL6RIL6 chimera at a concentration range of about 50-200 picogram per milliliter (μg/ml), wherein the culture medium is serum-free and capable of maintaining pluripotent stem cells in an undifferentiated state in the absence of feeder cell support.

### Claim 2 (depends on 1)

The culture medium of claim 1, wherein said culture medium further comprises serum replacement.

### Claim 3 (depends on 1)

The culture medium of claim 1, wherein said concentration of said IL6RIL6 chimera is between about 90 μg/ml to about 120 μg/ml.

### Claim 4 (depends on 1)

The culture medium of claim 1, wherein said concentration of said IL6RIL6 chimera is about 100 μg/ml.

### Claim 5 (depends on 1)

The culture medium of claim 1, wherein said culture medium is capable of maintaining and expanding said pluripotent stem cells in an undifferentiated state for at least 5 passages.

### Claim 6 (depends on 1)

The culture medium of claim 1, wherein said culture medium further comprises basic fibroblast growth factor (bFGF).

### Claim 7 (depends on 1)

A cell culture comprising pluripotent stem cells and the culture medium of claim 1.

### Claim 8 (depends on 7)

The cell culture of claim 7, wherein the cell culture is feeder cells free.

### Claim 9 (depends on 7)

The cell culture of claim 7, wherein said pluripotent stem cells are embryonic stem cells.

### Claim 10 (depends on 7)

The cell culture of claim 7, wherein said pluripotent stem cells are induced pluripotent stem (iPS) cells.

### Claim 11 (depends on 7)

The cell culture of claim 7, wherein said pluripotent stem cells are human pluripotent stem cells.

### Claim 12 (depends on 7)

The cell culture of claim 7, being a suspension culture.

### Claim 13 (depends on 1)

A method of deriving an embryonic stem cell line, comprising
(a) obtaining an embryonic stem cell from a pre-implantation stage blastocyst, post-implantation stage blastocyst and/or a genital tissue of a fetus; and
(b) culturing said embryonic stem cell in the culture medium of claim 1;
thereby deriving the embryonic stem cell line.

### Claim 14 (depends on 1)

A method of deriving an induced pluripotent stem cell line, comprising
(a) inducing a somatic cell to a pluripotent stem cell; and
(b) culturing said pluripotent stem cell in the culture medium of claim 1;
thereby deriving the induced pluripotent stem cell line.

### Claim 15 (depends on 1)

A method of expanding and maintaining pluripotent stem cells in an undifferentiated state, the method comprising culturing the pluripotent stem cells in the culture medium of claim 1, thereby expanding and maintaining the pluripotent stem cells in the undifferentiated state.

### Claim 16 (depends on 1)

A method of generating lineage-specific cells from pluripotent stem cells, the method comprising:
(a) culturing the pluripotent stem cells in the culture medium of claim 1, to thereby obtain expanded, undifferentiated stem cells;
(b) subjecting said expanded, undifferentiated stem cells to culturing conditions suitable for differentiating and/or expanding lineage specific cells;
thereby generating the lineage-specific cells from the pluripotent stem cells.

### Claim 17 (depends on 1)

A method of generating embryoid bodies from pluripotent stem cells, the method comprising:
(a) culturing the pluripotent stem cells in the culture medium of claim 1, to thereby obtain expanded, undifferentiated pluripotent stem cells; and
(b) subjecting said expanded, undifferentiated pluripotent stem cells to culturing conditions suitable for differentiating said stem cells to embryoid bodies;
thereby generating the embryoid bodies from the pluripotent stem cells.

### Claim 18 (depends on 1)

A method of generating lineage-specific cells from pluripotent stem cells, the method comprising:
(a) culturing the pluripotent stem cells in the culture medium of claim 1, to thereby obtain expanded, undifferentiated pluripotent stem cells;
(b) subjecting said expanded, undifferentiated pluripotent stem cells to culturing conditions suitable for differentiating said expanded, undifferentiated stem cells to embryoid bodies; and
(c) subjecting cells of said embryoid bodies to culturing conditions suitable for differentiating and/or expanding lineage specific cells;
thereby generating the lineage-specific cells from the pluripotent stem cells.

### Claim 19 (depends on 15)

The method of claim 15, wherein said culturing is effected on a matrix.

### Claim 20 (depends on 15)

The method of claim 15, wherein said culturing is effected in a suspension culture.

### Claim 21 (depends on 15)

The method of claim 15, wherein said culture medium is protein carrier-free.
